Soluble lectin-like oxidized low-density lipoprotein receptor-1 is increased in sera of chronic heart failure patients with left ventricular hypertrophy

Soluble lectin-like oxidized low-density lipoprotein receptor-1 is increased in sera of chronic heart failure patients with left ventricular hypertrophy

Hiromichi Wada1, Tomohide Takaya1,2, Tatsuya Morimoto3, Yoichi Sunagawa4, Masatoshi Fujita4, Takeshi Kimura2, Yoshiko Fujita5, Yuko Sato5, Tatsuya Sawamura5, Akira Shimatsu6, Koji Hasegawa1.

  1. Division of Translational Research, Kyoto Medical Center, National Hospital Organization, Kyoto, Japan.
  2. Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  3. Clinical Pharmacology and Therapeutics, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.
  4. Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  5. Department of Vascular Physiology, National Cardiovascular Center Research Institute, Osaka, Japan.
  6. Clinical Research Institute, Kyoto Medical Center, National Hospital Organization, Kyoto, Japan.

第13回日本心不全学会学術集会 (横浜), 2009/10/16-18.

Abstract

Background: Lectin-like oxidized low-density lipoprotein (oxLDL) receptor-1 (LOX-1) was originally identified as an endothelial receptor for oxLDL, and is now recognized as a multi-ligand receptor. Recently, we found that left ventricular (LV) expression of LOX-1 was markedly increased in the rat model of heart failure with LV hypertrophy (LVH). The extracellular domain of LOX-1 can be proteolytically cleaved and released into the blood stream in a soluble form (sLOX-1). However, the clinical significance of sLOX-1 in chronic heart failure (CHF) is unknown.

Methods and Results: We carried out a cross-sectional study including CHF patients with LVH (CHF-LVH) and apparently healthy subjects with normal LV dimensions and systolic function (control), and collected sera from them to measure the levels of sLOX-1. There were no significant differences in the age, body mass index, systolic and diastolic blood pressures, and heart rate between CHF-LVH and control groups. However, the LV end-diastolic dimension and LV mass index were significantly greater, and EF was significantly lower in the CHF-LVH than the control group. Interestingly, enzyme-linked immunosorbent assays revealed that serum levels of sLOX-1 were significantly increased in the CHF-LVH compared to the control group.

Conclusions: These findings support the need for further investigations to assess the clinical utility and prognostic value of serum levels of sLOX-1 in patients with CHF.